TD Cowen analyst Tyler Van Buren maintained a Buy rating on Artiva Biotherapeutics, Inc. (ARTV – Research Report) yesterday. The company’s shares closed yesterday at $3.91. Easily identify ...

Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating on Artiva Biotherapeutics, Inc. (ARTV – Research Report) on March 25 and set a price target of $20.00. The company’s shares ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Silencer Central became widely known in the firearm market largely due to the company's innovative sales platform and nationwide infrastructure that allowed it to ship suppressors directly to a ...

'There needs to be an overhaul of the entire system,' says Kory Wilson Indigenous justice experts are welcoming Canada's new Indigenous Justice Strategy, but some are disappointed at its lack of ...

MLB Opening Day 2025 is finally upon us and all eyes will be on the Los Angeles Dodgers after their World Series win in 2024. The Dodgers technically already opened their season with a sweep of ...

Inc.’s stock price changed recently Upgrades and downgrades for ARTV from analysts ARTV’s stock price momentum as measured by its relative strength Before we jump into Artiva Biotherapeutics, Inc.’s ...